Minnesota
Diabetes: Medtronic study finds pumps beat injections for patient satisfaction
Insulin pumps beat manual injections for managing symptoms of Type 2 diabetes, according to the latest results from Medtronic’s (NYSE:MDT) OpT2mise clinical trials.
TCT 2014: Medtronic’s IN.PACT Admiral beats PTA in outcomes, costs
Treasury Secretary Lew nears decision on Medtronic’s Covidien inversion deal
Medtronic launches personalized heart rhythm therapy trial
Another Covidien shareholder sues over Medtronic deal
New roster: Medtronic, Covidien reveal regional integration teams
Medtronic’s personalized pacemaker wins FDA approval
Press Release: Medtronic Viva cardiac resynchronization therapy-pacemaker now available in U.S.
MINNEAPOLIS – Medtronic, Inc. (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval of its newest cardiac resynchronization therapy-pacemaker, Viva® CRT-P, for indicated patients with heart failure or atrioventricular (AV) block.
Healthsense expands with $10M for remote monitoring
Minnesota remote care company Healthsense is looking to expand its reach with the $10 million in financing, eying opportunities in managed care and home health.